tiprankstipranks
Trending News
More News >

Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating. Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early proof-of-concept data for this asset could lead to substantial upside, the analyst tells investors in a research note. The firm also believes significant value can be unlocked for ATI-045 in asthma and other large respiratory indications after upcoming China Phase 2 data.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue